Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Gross Profit (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Gross Profit for 8 consecutive years, with $45.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 5109.67% to $45.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $196.7 million, a 181.17% increase, with the full-year FY2025 number at $196.7 million, up 102.81% from a year prior.
  • Gross Profit was $45.1 million for Q4 2025 at Akebia Therapeutics, down from $49.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $142.2 million in Q4 2022 to a low of -$17.0 million in Q4 2021.
  • A 5-year average of $39.6 million and a median of $30.9 million in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: plummeted 118.64% in 2021, then soared 30525.84% in 2022.
  • Akebia Therapeutics' Gross Profit stood at -$17.0 million in 2021, then surged by 937.42% to $142.2 million in 2022, then crashed by 67.27% to $46.5 million in 2023, then crashed by 101.93% to -$900000.0 in 2024, then surged by 5109.67% to $45.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Gross Profit are $45.1 million (Q4 2025), $49.4 million (Q3 2025), and $52.6 million (Q2 2025).